Acuataas Chemicals leads the sector with strong 1-month returns of nearly 30%, signaling robust investor confidence.
Neuland Labs shows high growth potential with a premium valuation driven by strong R&D and niche APIs.
Sun Pharma remains the most stable and dominant player in India’s healthcare and pharmaceutical market.
The Indian healthcare sector is showing strong growth potential as the demand for quality medical care and pharmaceutical products is increasing. It is one of the most promising investment areas, supported by government policies, global demand, and technological advancement.
Several companies focusing on innovation, exports, and healthcare infrastructure have delivered impressive returns in the last few months. Each company has a different business model, market position, and financial strength. This article will explore them in detail to understand why they are among the best healthcare stocks to consider.
Acuataas Chemicals is one of the best-performing healthcare stocks. The company’s latest trading price (LTP) stands at Rs. 1,710.50, showing a 1.25% daily gain and a 29.80% return in one month. With a market capitalization of Rs. 14,004 crore and a PE ratio of 61.77, it is trading slightly above the industry PE of 58.92.
The company specializes in manufacturing essential chemicals used in the pharmaceutical and healthcare industries. Its strong profitability, consistent trading volume of 25,660 shares, and proximity to its 52-week high of Rs. 1,868.20 indicate strong investor confidence. Over the past month, Acuataas Chemicals has outperformed many of its competitors, making it a potential multibagger candidate if it sustains its earnings momentum.
Divis Laboratories is one of the most established players in the pharmaceutical sector. With an LTP of Rs. 6,568.00 and a market cap of Rs. 1,74,360 crore, it is supported by institutional investors. The company’s PE ratio of 74.94 is slightly above the industry average, indicating a premium valuation driven by its reputation, export quality, and strong research capabilities.
Last month, Divis Laboratories delivered a 15.44% return, with a strong recovery in the global active pharmaceutical ingredients (API) market. The stock’s 52-week range, from Rs. 4,955.00 to Rs. 7,071.50, suggests that it is trading close to its yearly high, reflecting investor optimism about its future performance.
Laurus Labs, with a market capitalization of Rs. 51,381 crore, has built a strong presence in the pharmaceutical manufacturing and contract research segment. Its LTP is Rs. 951.80, showing a small daily decline of -1.03%. Despite short-term volatility, the stock has given a 13.07% return in one month.
The company has maintained a healthy PE ratio of 76.13, which indicates investor confidence in its future growth. Laurus Labs’ 52-week high of Rs. 970.00 and low of Rs. 474.05 suggest significant appreciation potential over the medium term. The company is focused on expanding its API and formulation segments, supported by increasing global demand for affordable medicine.
Aster DM Healthcare is one of India’s most prominent healthcare service providers, operating hospitals and clinics across multiple regions. The stock is currently priced at Rs. 695.20, with a market cap of Rs. 36,020 crore. Its PE ratio stands at 103.76, which is substantially higher than the industry average of 33.82. This indicates strong investor growth expectations.
Despite a slight -0.66% daily dip, Aster DM Healthcare has shown a 10.89% return over the last month. Its 52-week high of Rs. 732.20 and low of Rs. 387.10 highlight the company’s consistent upward trajectory. The healthcare firm continues to benefit from the increasing demand for quality private healthcare facilities and medical tourism.
Also Read: Dividend Payments Explained: How and Why Companies Distribute Profits
Granules India, a mid-cap pharmaceutical company, trades at Rs. 571.65 with a modest 0.06% daily gain and a market cap of Rs. 13,872 crore. The company’s PE ratio of 28.91 is below the industry average of 55.41, suggesting the stock may still be undervalued relative to peers. It has delivered a 10.57% return in one month.
Granules has maintained a steady operational performance and a robust product pipeline. Its 52-week range between Rs. 422.00 and Rs. 628.00 reflects moderate volatility and steady investor interest. For long-term investors looking for value, Granules India is a stable option with solid fundamentals.
Biocon is one of India’s largest biopharmaceutical companies, with a market cap of Rs. 49,862 crore. The current LTP is Rs. 372.95, showing a minor -0.20% change. Its PE ratio of 76.08 matches closely with its industry average of 55.41, showing fair valuation given its growth prospects.
The stock has delivered a 9.37% return in the past month, indicating improving investor sentiment. Biocon is making great progress in biosimilars, insulin products, and research collaborations with global pharmaceutical companies. The company’s 52-week high of Rs. 406.00 suggests the potential for near-term appreciation if earnings growth sustains.
Fortis Healthcare is a major private hospital chain in India, with an LTP of Rs. 1,052.20 and a market cap of Rs. 79,437 crore. The company’s PE ratio is 88.32, reflecting optimism about its growth in the healthcare services segment. The stock has declined 0.31% today but maintains an 8.50% one-month gain.
Fortis operates a vast network of hospitals and diagnostic centers across the country. Its 52-week range between Rs. 577.00 and Rs. 1,104.30 shows impressive appreciation. The company’s focus on expanding capacity, improving patient care, and enhancing operational efficiency positions it well for long-term growth.
Neuland Laboratories has gained attention with its strong performance. The company’s stock trades at Rs. 15,721.00, gaining 2.04% in a day and delivering a 7.64% return in one month. With a market cap of Rs. 20,170 crore and a PE ratio of 111.98, it holds a premium valuation due to its niche capabilities in complex APIs.
The 52-week range between Rs. 10,190.70 and Rs. 18,100.00 suggests significant momentum. Neuland’s focus on high-value, low-volume products and strong R&D capabilities makes it one of the most promising mid-cap pharma stocks.
Sai Life Sciences has an LTP of Rs. 913.75 with a -0.33% daily change and a market cap of Rs. 19,120 crore. The PE ratio is 78.85, above the industry average of 26.42, suggesting growth potential. The stock has shown a 6.16% return in one month, suggesting improving performance.
The company focuses on contract research and manufacturing services (CRAMS) for global pharmaceutical players. With a 52-week high of Rs. 943.00, Sai Life Sciences is expected to continue benefiting from outsourcing demand in global pharma manufacturing.
Also Read: Growth vs Income Stocks: What to Know Before Investing
Sun Pharmaceutical remains India’s largest pharma company by market capitalization, currently valued at Rs. 4,04,192 crore. The LTP is Rs. 1,684.60, with a -1.82% daily change but a 5.66% one-month return. Its PE ratio of 39.61 is well-balanced relative to the industry PE of 55.41.
The company’s broad product portfolio, strong global presence, and consistent profitability make it a reliable choice for long-term investors. Its 52-week high of Rs. 1,910.00 and low of Rs. 1,548.00 indicate steady performance and limited downside risk.
The healthcare and pharmaceutical sector in India is set for strong growth in 2025 and beyond. Companies like Acuataas Chemicals, Divis Laboratories, and Sun Pharmaceutical are strong performers with solid fundamentals and consistent earnings.
Others like Laurus Labs, Neuland Laboratories, and Biocon offer great potential for medium to long-term appreciation. With growing domestic healthcare demand, increasing exports, and government support for innovation, these stocks offer stability and a decent probability for good returns.
Some of the best healthcare stocks to consider in 2025 include Acuataas Chemicals, Divis Laboratories, Neuland Labs, Sun Pharma, and Laurus Labs, which have shown strong financial performance and consistent returns.
2. Why is Acuataas Chemicals considered a top performer?
Acuataas Chemicals has delivered nearly 30% returns in the past month, supported by rising demand in the pharmaceutical chemical segment and strong market fundamentals.
3. Is Neuland Labs a good long-term investment?
Yes, Neuland Labs is a promising long-term investment due to its high-value API portfolio, solid R&D strength, and growing international presence in niche pharmaceutical products.
4. How has Sun Pharma performed recently?
Sun Pharma remains India’s largest and most stable pharma company, offering steady growth and profitability with a diversified product base and global reach.
5. Are healthcare stocks a safe investment in 2025?
Healthcare stocks are considered relatively safe and resilient investments, as demand for medicines, diagnostics, and medical services continues to grow regardless of market cycles.